GREENWICH, Conn., March 15, 2012 /PRNewswire/ -- Timothy C. Tyson, Aptuit Chairman, announced that effective immediately, Stuart E. Needleman has been named President and Chief Operating Officer of Aptuit LLC. Following the recent sale of the company's Clinical Trials Supply Business, Mr. Needleman has been promoted from his previous position at Aptuit as President, Scientific Operations. In his new role, Mr. Needleman is responsible for all day-to-day operations of the worldwide Aptuit organization, reporting directly to the company's Board.
(Logo: http://photos.prnewswire.com/prnh/20120217/NY55633LOGO )
In accepting this appointment, Mr. Needleman stated, "I am looking forward to this opportunity to lead the continued growth of Aptuit during the exciting days ahead. I believe that our comprehensive early to mid-phase drug development services, distinguished by our industry leading scientific expertise, are second to none. As we welcome new clients and continue our relationships with those who show their confidence in Aptuit again and again, we are enthusiastic about the future, and we remain dedicated to forging more robust strategic relationships."
In making the announcement, Tim Tyson reported that he will continue in his role as Chairman and will concentrate his efforts on a variety of external growth and strategic partnership opportunities. Mr. Tyson cited Mr. Needleman's recent success as President of Aptuit's Scientific Operations and his substantial industry standing. "Stu is a seasoned veteran with a legacy of more than 30 years of successful sales, marketing and operations experience in drug development services. All of us at Aptuit congratulate him as he leads in building a strong business model based on our solid reputation for scientific excellence."
Mr. Needleman began his career at Cambrex, and previously held senior level, global positions at Oxford Asymmetry, ChiRex, Rhodia Pharma Solutions and Arch Pharmalabs. Mr. Needleman joined Aptuit in 2006 as Vice President, Sales and Marketing, and was later promoted to President of API Development and Manufacturing. In 2011, Mr. Needleman was placed in charge of all the company's scientific efforts as President of Aptuit Scientific Operations. Mr. Needleman earned an MBA and BSc in Chemical Engineering from Rensselaer Polytechnic Institute (RPI).
Stu Needleman resides in Trumbull, CT with his wife and daughter. He is active in numerous local and regional organizations, serving on the Boards of Trumbull Babe Ruth baseball and Trumbull Pisces swimming. Stu and his wife are also active supporters of the Strike 3 Foundation for childhood cancer research.
For more information, please contact Maria Garvey, Delfino Marketing at 914-747-1400 or email@example.com.
Aptuit is a global pharmaceutical services company focusing on delivering contract development and manufacturing services and streamlining the drug development process for biotechnology and pharmaceutical innovators. Aptuit's employees deliver an integrated suite of product development services to more than 800 companies worldwide driven by a deep commitment to client service, quality and an unrivaled track record of scientific excellence. The company is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors. For more information about Aptuit, visit www.aptuit.com
Aptuit: engineering a better drug development process through scientific excellence